The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Magnesium citrate

Magnesium citrate

Magnesium citrate is a widely used magnesium supplement that can help support healthy magnesium levels.
It is often used to address magnesium deficiencies and may provide additional health benefits.
PubCompare.ai's AI-powered platform can help researchers optimize their protocols for studying magnesium citrate, locating the best published methods and identifying the most effective products.
This can streamline research efforts and enhance reproducibility, leading to improved results.

Most cited protocols related to «Magnesium citrate»

Yeast Strains and Constructs—The following yeast strains were used: BY4741 (MATa his3Δ1 leu2Δ met15Δ ura3Δ) and NDY257 (BY4741 rtn1::kanMX4 rtn2::kanMX4 yop1::kanMX) (6 (link)). Strains expressing GFP fusions to the chromosomal alleles of YOP1 and RTN1 were obtained from Invitrogen. The plasmid encoding Sec63-GFP (pJK59) has been previously described (12 (link)). To make the plasmid encoding Rtn1-GFP (pCV19), the SEC63 portion of pJK59 was removed by digestion with XbaI and XhoI. The RTN1 gene, including 400 bp upstream of the start site, was PCR-amplified from yeast chromosomal DNA and inserted into the same sites.
Mammalian Plasmid Constructs—HA-DP1 was described previously (6 (link)). HA-Rtn3c was cloned by PCR amplifying Rtn3c (NCBI accession number: BC036717) from mouse cDNA with primers containing an N-terminal HA tag and inserted into pcDNA3.1D (Invitrogen). For Rtn4a-GFP, human Rtn4a was PCR-amplified from Rtn4a-Myc (described in a previous study (6 (link))) and ligated into the pAcGFP-N1 backbone (Clontech) using the XhoI and KpnI restriction sites at the 5′ and 3′ ends, respectively. For GFP-Rtn3c, Rtn3c was PCR-amplified from HA-Rtn3c and ligated into the pAcGFP-C1 backbone (Clontech) using the XhoI and EcoRI restriction sites. To clone GFP-Rtn4HD, the region encoding amino acids 961–1192 was PCR-amplified from human Rtn4a-Myc and inserted into pAcGFP-C1 using the XhoI/EcoRI restriction sites. GFP-DP1 was subcloned by PCR-amplifying mouse DP1 from HA-DP1 (described in a previous study (6 (link))) and inserting into pAc-GFP C1 using SacI/BamHI restriction sites. For GFP-Climp63, Climp63 was PCR-amplified from mouse cDNA and cloned into pAcGFP-C1 using the XhoI/EcoRI sites. Climp63Δlum-GFP was cloned by PCR amplifying the region encoding amino acids 1–115 (as described in (13 (link))) from GFP-Climp63 and inserted into pAcGFP-N1 using XhoI/EcoRI restriction sites. LBR-GFP was PCR-amplified from plasmid containing human LBR (14 (link)) and cloned into pAcGFP-N1 using the XhoI/BamHI restriction sites. For GFP-Sec61β, human Sec61β was PCR-amplified from the pcDNA3.1/GFP-Sec61β construct described previously (6 (link)), and inserted into pAcGFP-C1 using the BglII/EcoRI restriction sites. RFP-Sec61β was subcloned from GFP-Sec61β using the same restriction sites as above and inserted into an mRFP1 vector (pEGFP-C1 vector backbone where pEGFP has been replaced with mRFP1).
Microscopy of Yeast—Yeast strains were grown in synthetic complete medium (0.67% yeast nitrogen base and 2% glucose) and imaged live at room temperature using an Olympus BX61 microscope, UPlanApo 100×/1.35 lens, QImaging Retiga EX camera, and IPlabs version 3.6.4 software.
Screen for Mutations in Yeast RTN1 That Affect Localization—Error-prone PCR on RTN1 was performed using the GeneMorphII Random Mutagenesis Kit (Stratagene). The product of this reaction and pJK59 cut with XbaI and XhoI were used to transform wild-type yeast. Transformants were visually screened for those that showed perinuclear GFP localization.
Tissue Culture, Indirect Immunofluorescence, and Confocal Microscopy of COS-7 Cells—Cells were grown at 37 °C with 5% CO2 in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and subcultured every 2–3 days. Transfection of DNA into cells was performed using Lipofectamine 2000 (Invitrogen). After 5 h of transfection, cells were split onto acid-washed No. 1 coverslips and allowed to spread for an additional 24–36 h before being processed for indirect immunofluorescence.
For immunofluorescence, transfected cells were fixed in PBS containing 4% paraformaldehyde (Electron Microscopy Sciences) for 15 min, washed twice, and permeabilized in 0.1% Triton X-100 (Pierce) in PBS for 5–15 min. Cells were washed twice again and then probed with primary antibodies for 45 min in PBS containing 1% calf serum, at the following concentrations: rat anti-HA antibody (Roche Applied Science) at 1:200 dilution; mouse anti-αtubulin (Sigma) at 1:500 dilution; and rabbit anti-calreticulin antibody (Abcam) at 1:500 dilution. Cells were washed three times in PBS, and then incubated with various fluorophore-conjugated secondary antibodies for an additional 45 min (Alexafluor 488 or 555 anti-mouse at 1:250 dilution, Alexafluor 647 anti-rabbit 1:500 dilution, and Alexafluor 488 anti-rat 1:200 dilution (all from Invitrogen)). Cells were then washed and mounted onto slides using Fluoromount-G mounting medium (Southern Biotech).
All imaging for indirect immunofluorescence was captured using a Yokogawa spinning disk confocal on a Nikon TE2000U inverted microscope with a 100× Plan Apo numerical aperture 1.4 objective lens, and acquired with a Hamamatsu ORCA ER cooled charge-coupled device camera using MetaMorph 7.0 software. For image presentation, brightness and contrast were adjusted across the entire image using Adobe Photoshop 7.0, and images were converted from 12 to 8 bits.
Transmission Electron Microscopy—COS-7 cells expressing GFP-Rtn4HD were sorted in a MoFlo cell sorter (Cytomation). The resulting cell pellet was fixed for 1 h in a mixture of 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 m sodium cacodylate buffer (pH 7.4), washed in 0.1 m cacodylate buffer, and postfixed with a mixture of 1% OsO4 and 1.5% KFeCN6 for 30 min. The pellet was then washed in water and stained in 1% aqueous uranyl acetate for 30 min followed by dehydration in grades of alcohol (50%, 70%, and 95%, 2 × 100%). Next, the pellet was infiltrated in a 1:1 mixture of propylene oxide and TAAB Peon (Maria Canada Inc.) for 2 h, placed in pure TAAB Epon in a silicon-embedding mold, and polymerized at 65 °C for 48 h. Ultrathin sections (∼60–80 nm) were cut on a Reichert Ultracut-S microtome, placed onto copper grids, and stained with 0.2% lead citrate. Specimens were examined on a Tecnai G Spirit BioTWIN transmission electron microscope, and images were acquired with a 2k AMT charge-coupled device camera.
Fluorescence Recovery after Photobleaching—Transfected COS-7 cells were imaged in phenol red-free HyQ DME (HyClone) supplemented with 25 mm Hepes, pH 7.4, and 1% fetal bovine serum. FRAP experiments were conducted on a Zeiss LSM 510 NLO laser scanning inverted microscope using a Plan-Neofluor 100×/1.3 oil objective with argon laser line 488 nm (optical slices <1.2 mm for COS-7 and 4.2 μm for yeast). Mammalian cell experiments were done at 37 °C using an objective heater (Bioptechs) and an enclosed stage incubator (Zeiss). LSM 510 software version 3.2 was used for image acquisition and analysis. Magnification, laser power, and detector gains were identical across samples.
For all mammalian experiments, COS-7 cells were treated with 0.5 μm nocodazole, and all data were collected during the first 5–30 min of nocodazole addition. For photobleaching all constructs, except for LBR-GFP, the tubular ER was magnified using the 3× zoom function so that individual tubules could be seen clearly. For LBR-GFP, the microscope was focused onto the bottom of the nuclear envelope. Images taken for 5-s prebleaching, whereupon a region of interest of 65 × 65 pixels was photobleached at 100% laser power. After the photobleaching, images were taken at 1-s intervals for 75–300 s. Yeast cells were treated similarly except that the region of interest was 17 × 17 pixels, and images were taken every 2–4 s at room temperature.
Raw data were quantitated using Zeiss LSM510Meta software. For analysis, the fluorescence intensity of three regions of interest was measured: the photobleached region (PR), a region outside of the cell to check for overall background fluorescence (BR), and a region within the cell that was not photobleached to check for overall photobleaching and fluorescence variation (CR), for the entire course of the experiment. Microsoft Excel was used to normalize the relative fluorescence intensity, I, for each individual FRAP experiment using Equation 1. For data presentation, the mean averages of the normalized data for each set of FRAP experiments were plotted using GraphPad Prism 5.0, and fluorescence recovery curves were shown for the first 80–140 s of each experiment. Estimated half-times of recovery and mobile fraction values were calculated using the standard Michaelis-Menten equation.
Sucrose Gradient Centrifugation—For yeast sucrose gradient analysis, crude membranes were isolated from yeast strains expressing GFP-fused proteins at endogenous levels as follows: 200 ml of culture were grown to OD ∼1, pelleted and then resuspended in TKMG lysis buffer (50 mm Tris, pH 7.0, 150 mm KCl, 2 mm MgCl2, 10% glycerol, 1 mm EDTA, 1 mm PMSF, 1 mm 4-(2-aminoethyl)benzenesulfonylfluoride hydrochloride), flash frozen in liquid nitrogen, and ground using a mortar and pestle. Cell debris was separated from the lysate by low speed centrifugation for 5 min at ∼2,000 × g. Membranes were then pelleted by ultracentrifugation for 15 min at 100,000 × g and solubilized in 200 μl of TKMG buffer containing 1% digitonin. Solubilized lysate was centrifuged for 10 min at 12,000 × g to separate out any remaining cell debris. 100-μl of lysate were run on 5–30% w/v sucrose gradients for 4 h at 166,000 × g at 25 °C on a Beckman TLS55 rotor. Twenty gradient fractions were collected from top to bottom and analyzed by SDS-PAGE and immunoblotting with anti-GFP antibody (Roche Applied Science). 50 mg of apoferritin, catalase, and aldolase was used as molecular weight standards.
Xenopus washed membrane fractions were prepared in MWB (50 mm Hepes, pH 7.5, 2.5 mm MgCl2, 250 mm sucrose, and 150 mm potassium acetate) as previously described (6 (link)), incubated for 60 min at 25 °C in MWB containing 200 mm KCl and 0.5 mm GTP, and then solubilized for 30 min at 25 °C with either 2% Nonidet P-40 or 1.25% digitonin. Samples were pelleted for 15 min at 12,000 rpm, and the soluble fraction was loaded onto a 10–30% w/v sucrose gradient made with MWB containing 200 mm KCl, 0.1 mm GTP, and either 0.1% Nonidet P-40 or 0.1% digitonin, respectively. The sucrose gradient was centrifuged for 3 h, 45 min at 55,000 rpm. Sixteen gradient fractions were collected and analyzed by SDS-PAGE and immunoblotted with antibody against Xenopus Rtn4 (described in a previous study (6 (link))).
For mammalian sucrose gradient analysis, COS-7 cells transiently transfected with HA-DP1 or GFP-Sec61β were harvested by scraping and then lysed and solubilized in HKME buffer (25 mm Hepes, pH 7.8, 150 mm potassium acetate, 2.5 mm magnesium acetate, 1 mm EDTA, and 2 mm PMSF) containing 1% digitonin for 1 h. The lysate was clarified by centrifugation at 10,000 × g for 10 min, and 100 μl of clarified lysate was sedimented on 5–30% w/v sucrose gradients under the same conditions as yeast. Fractions were analyzed by SDS-PAGE and immunoblotting with anti-HA antibody or anti-Sec61β antibody (described in a previous study (15 (link))).
Chemical Cross-linking Experiments—Yeast crude membrane fractions were resuspended in buffer containing 50 mm Hepes, pH 7.0, 150 mm KCl, and 1 mm PMSF. Ethylene glycobis(succinimidylsuccinate) (EGS, Pierce), was dissolved in anhydrous DMSO and diluted to the desired concentration. 1 μl of EGS was added into every 20 μl of protein-containing sample for 30 min at room temperature. The reactions were quenched for 15 min with 2 μl of 1 m Tris, pH 7.5. Samples were analyzed on a 4–20% SDS-PAGE and immunoblotted using standard procedures with mouse anti-His or rat anti-HA antibody conjugated to peroxidase (Sigma).
For mammalian cross-linking experiments, transfected COS-7 cells were grown in a 10-cm plate to ∼80% confluency and then lysed using a standard hypotonic lysis protocol. Briefly, cells were harvested in PBS, washed, incubated in hypotonic buffer (10 mm Hepes, pH 7.8, 10 mm potassium acetate, 1.5 mm magnesium acetate, 2 mm PMSF) for 10 min, and then passed through a 25-gauge syringe ten times. Nuclei and any remaining intact cells were separated from the lysate by centrifugation for 5 min at 3,000 × g, and the supernatant was then centrifuged for 10 min at 100,000 × g to pellet the membrane fraction. The membrane pellet was washed in HKM buffer (25 mm Hepes pH 7.8, 150 mm potassium acetate, 2.5 mm magnesium acetate, and 2 mm PMSF), repelleted at 100,000 × g, and resuspended to a final volume of 60 μl in HKM buffer. 10-μl membrane aliquots were used for each cross-linking reaction using the same conditions as above. Samples were analyzed on a 4–20% SDS-PAGE and immunoblotted using standard procedures with anti-HA antibody.

Rtn1p and Yop1p have slow diffusional mobility in the ER of yeast cells. A, typical FRAP of Sec63-GFP or Rtn1-GFP in S. cerevisiae cells expressed at endogenous levels. Images were taken before and then after the photobleach for the times indicated. The boxed region shows the area that was photobleached. B, fluorescence intensities normalized to prebleach values of FRAP analyses on yeast Sec63-GFP, Rtn1-GFP, and Yop1-GFP were plotted over time. Error bars indicate ± S.E.; n = 4 cells. C, fluorescence intensities normalized to prebleach values plotted over time of FRAP analyses on yeast Rtn1p in ATP-depleted (green) or non-depleted (orange) cells, compared with that of Sec63p-GFP (ATP depleted in blue; non-depleted in red). Error bars indicate ± S.E., n = 4 cells.


ATP Depletion Experiments—For yeast experiments, ATP was depleted by the addition of 10 mm 2-deoxy-d-glucose and 10 mm sodium azide (both from Sigma) for 2–5 min, and FRAP experiments were performed using the same parameters as described above. Similarly, for mammalian cell experiments, COS-7 cells were depleted of ATP as follows: transfected cells were washed twice in Opti-Mem serum-free media (Invitrogen) and then incubated with 50 mm 2-deoxy-d-glucose and 0.02% sodium azide in glucose-free imaging buffer (50 mm Hepes, pH 7.4, 150 mm potassium acetate, 2.5 mm magnesium acetate, and 1% fetal bovine serum). FRAP experiments were conducted in the same medium and completed within 5–30 min of treatment using the same parameters as above.
Publication 2008
Human urine is composed primarily of water (95%). The rest is urea (2%), creatinine (0.1%), uric acid (0.03%), chloride, sodium, potassium, sulphate, ammonium, phosphate and other ions and molecules in lesser amounts30 (Table 1). Protein is only found in trace amounts compared to their values in blood plasma. A recent study published by Bouatra and co-workers (2013)1 (link) revealed more than 3000 components in human urine. From the complete list of components published in the same study, there are over 90 compounds with 100% occurrence composing the urine regardless of the gender or the time of the day that the urine is collected. For a practical and economical AU formulation, the number of ingredients to be used in MP-AU is kept to a minimum; thus, only the components with relatively higher concentration compared to others are selected and used.

Physiological ranges of selected compounds in healthy human urine.

Property and CompositionMolar Mass (g/mol)Normal Range in humans (reference age in years)Molarity (mmol/1.5 L)
Volume0.8–2 L
pH4.5–8.0
Specific gravity (SG)1.002–1.030 g/ml (all)
Osmolality150–1150 mOsm/kg (>1)
Urea (CH4N2O)60.0610–35 g/d (all)249.750
Uric Acid (C5H4N4O3)168.11<750 mg/d (>16)1.487
Creatinine (C4H7N3O)113.12Males: 955–2936 mg/d7.791
Females: 601–1689 mg/d (18–83)
Citrate (C6H5O73−)192.12221–1191 mg/d (20–40)2.450
Sodium (Na+)22.9941–227 mmol/d (all)92.625
Potassium (K+)39.1017–77 mmol/d (all)31.333
Ammonium (NH4+)18.0515–56 mmol/d (18–77)23.667
Calcium (Ca2+)40.08Males:<250 mg/d1.663
Females:<200 mg/d (18–77)
Magnesium (Mg2+)24.3151–269 mg/d (18–83)4.389
Chloride (Cl)35.4540–224 mmol/d (all)88.000
Oxalate (C2O42−)88.020.11–0.46 mmol/d (all)0.277
Sulphate (SO42−)96.067–47 mmol/d (all)18.000
Phosphate (PO42−)94.9720–50 mmol/d (>18)23.33
Table 1 shows the physiological ranges of selected compounds in healthy human urine. The data has been retrieved from Mayo Medical Laboratories31 , which is a global reference laboratory operating within the Mayo Clinic’s Department of Laboratory Medicine and Pathology. The mean values of the ranges given for each component are used to prepare MP-AU. The concept of ‘normal’ also depends on gender for calcium and creatinine. For these two components, a normal range is determined for both male and female that falls within the normal for both sexes in this study. For example, a range of 955–1689 mg/d of creatinine is taken to be the normal physiological range, so that, even at extreme points, the given amount is still ‘normal’ for both genders.
The normal volume range of urine output is 0.8 to 2 l/d for a person having a normal fluid intake. For molarity calculation of each compound, 1.5 l/d is assumed for an average person32 (link)–34 (link). The right-most column in Table 1 shows the basis of MP-AU composition as well as the concentrations of each compound. Table 2 provides a complete list of the MP-AU components and their final concentrations. All chemicals used in this study are in powder form, purchased from Merck (Germany) and used without further purification. The components are dissolved in 100 ml double-distilled water using a magnetic stirrer (Heidolph, Germany) rotating at 250–500 rpm. During mixing, the temperature of the solution is kept constant at 37.5 °C using the heater function of the stirrer. The same procedure is followed for all AUs.

The composition of MP-AU.

Molarity (mM)Quantity (g/100 ml)
Na2SO411.9650.1700
C5H4N4O31.4870.0250
Na3C6H5O7.2H2O2.4500.0720
C4H7N3O7.7910.0881
CH4N2O249.7501.5000
KCl30.9530.2308
NaCl30.0530.1756
CaCl21.6630.0185
NH4Cl23.6670.1266
K2C2O4.H2O0.190.0035
MgSO4.7H2O4.3890.1082
NaH2PO4.2H2O18.6670.2912
Na2HPO4.2H2O4.6670.0831
After the preparation of AUs, they are tested using semi-quantitative urine dipsticks (Mission Acon, San Diego, USA). The tests are performed according to the manufacturer’s instructions. Also, a Mettler-Toledo pH meter (Schwerzenbach, Switzerland) is used for pH measurements. A freshly prepared solution is always used for measurements. When the components are added in the order provided in Table 2, the pH of the solution is stabilized around 6.00 ± 0.08 after 24 h at 37 °C. Therefore, for pH sensitive studies, it is recommended to prepare the AU solution one day prior to the research study. The repeatability of the MP-AU is tested by preparing three samples and recording their FTIR spectra (Supplementary Fig. S1). Results show that the MP-AU solution is reproducible.
In this study, we prepared three artificial urine batches. Together with our own formulation (MP_AU), other two are based on the protocol published by Chutipongtanate and Thongboonkerd (called CT-AU) (2010)12 (link), and Brooks and Keevil (called BK-AU) (1997)10 (link). The list of components and concentrations can be found in Supplementary Table S1. In the preparation of BK-AU, yeast and peptone are not used. In the original study, these compounds were used to examine the growth of urinary pathogens10 (link). The measurements are also repeated three times for CT- and BK-AU (Supplementary Fig. S1). Average of three measurements for all AU formulations are calculated and used for comparison with human urine.
The infrared absorbance of each component in the formulation of MP-AU is obtained by dissolving the appropriate amount (as in Table 2) in 100 ml double-distilled water. In this way, 13 batches of solutions, each containing a different component are prepared and measured individually. As a result, a spectral library of each component used in this study is obtained.
Full text: Click here
Publication 2019

Source DNA and Cloning—Cultured Vero cells were infected with SARS coronavirus strain HKU 39487. Total RNA was isolated with TRIZOL (Invitrogen) as instructed by the manufacturer. Purified RNA was reverse-transcribed using Superscript II reverse transcriptase (Invitrogen) and random hexamers. The NTPase/helicase domain (nsP10) was amplified by PCR, using AmpliTaq Gold (Applied Biosystems) with the forward primer 5′-GGCGGATCCGCCATGGCTGTAGGTGCTTGTGTATTG-3′ and the reverse primer 5′-GGCCTCGAGTCATTGTAATGTAGCCACATTGCG-3′. The PCR product was gel purified, digested with BamHI/XhoI and ligated with a similarly digested pET28a(+) vector (Novagen) to make the plasmid pHelA12.
Protein Purification—4 liters of LB broth supplemented with kanamycin (50 μg/ml) were inoculated with saturated pHelA12/BL21 (DE3) culture (1/200 dilution) and grown at 37 °C until A600 = 0.6. Protein expression was induced by addition of isopropyl-1-thio-β-d-galactopyranoside (0.5 mm), and cultures were incubated at 25 °C for 6 h. After cooling to 4 °C, the cells were harvested by centrifugation and resuspended in Buffer A (25 mm Tris-HCl, pH 6.8, 20 mm imidazole, 0.5 m NaCl, 0.1% Triton X-100, protease inhibitors (Complete, Roche Applied Science), 1 g of wet cell pellet/5 ml of buffer). Cells were lysed by sonication (Sonics VibraCell, microtip, 30% power for 3 min (4 s on, 10 s off) with ice cooling) and then centrifuged (30 min, 30,000 × g), and the supernatant was filtered (Corning syringe filter, 0.45 μm) and then applied to 2 × 5 ml nickel-charged HiTrap chelating columns directly connected in series (Amersham Biosciences). The 10-ml column was washed with 100 ml of Buffer A, then 50 ml Buffer B (25 mm Tris-HCl, pH 6.8, 50 mm imidazole, 0.5 m NaCl) before eluting the protein with a stepwise gradient over 100 ml versus Buffer C (25 mm Tris-HCl, pH 6.8, 250 mm imidazole, 0.5 m NaCl). Collected fractions (2 ml) were immediately diluted with 2 ml of Buffer D (20 mm Tris-HCl, pH 6.8, 5 mm β-mercaptoethanol (β-ME), 10% glycerol) to reduce protein precipitation. The purest fractions (determined by SDS-PAGE) were combined, dialyzed against 500 volumes of Buffer D, and then filtered (0.45 μm) before application to a column containing 0.5 ml of Red Sepharose CL-6B resin (Amersham Biosciences). The resin was washed with 5 ml of Buffer B (containing 5 mm β-ME), before elution with a stepwise gradient over 10 ml versus Buffer E (25 mm Tris-HCl, pH 6.8, 50 mm imidazole, 2 m NaCl, 5% glycerol, 5 mm β-ME, 2% Nonidet P-40). Pure fractions (by SDS-PAGE) were combined and stored at 4 °C for short term or frozen at –70 °C for long term storage.
NTPase Assays—NTPase assays were performed by measuring phosphate release using a colorimetric method based on complexation with malachite green and molybdate (AM/MG reagent) (17 (link), 18 (link)). In a 50-μl volume, typically 0.2–0.7 pmol of protein, 50 mm Tris-HCl, pH 6.6, 5 mm MgCl2, 1 mm ATP, and 25 μg/ml poly(U) (Amersham Biosciences, s20,w = 4.8) were incubated for 10 min at 25 °C. The reaction was stopped by the addition of 10 μl of 0.5 m EDTA, and then the color was developed for 5 min following the addition of 200 μl of AM/MG reagent (0.034% malachite green, 1.05% ammonium molybdate, 0.04% Tween 20, in 1 m HCl). 40 μl of 34% (w/v) trisodium citrate dihydrate was then added and the A630 read, typically using a 96-well plate reader. For the assays stimulated by homopolynucleotides, the polynucleotide concentration was accurately measured using the A260 and quoted as a molar concentration of 24-mer. The amount of phosphate released was quantified by comparison with a standard phosphate calibration curve. Data were fitted using Origin (Microcal Software).
Preparation of Duplex DNA Substrates—The synthetic oligonucleotide “released” (5′-GGTGCAGCCGCAGCGGTGCTCG-3′, Proligo (Singapore), de-salted) was labeled with [γ-32P]ATP (3000 Ci/mmol, Amersham Biosciences) using T4 polynucleotide kinase (Amersham Biosciences) according to the manufacturer's instructions. Labeled DNA was purified by desalting (AutoSeq G-50 spin column, Amersham Biosciences), phenol:chloroform extraction, and ethanol precipitation and was resuspended in deionized water. The labeled released oligo (100 pmol) was annealed to 150 pmol of oligos “Tblunt” (5′-CGAGCACCGCTGCGGCTGCACC-3′), “3T20” (5′-CGAGCACCGCTGCGGCTGCACCTTTTTTTTTTTTTTTTTTTT-3′), and “5T20” (5′-TTTTTTTTTTTTTTTTTTTTCGAGCACCGCTGCGGCTGCACC-3′) in 100 μl of Buffer F (25 mm Hepes, pH 7.4, 1 mm EDTA, 25 mm NaCl) by heating to 95 °C for 5 min, followed by gradual cooling to room temperature at 0.5–1 °C/min, to form substrate DNA duplexes dB, d3T, and d5T, respectively. DNA duplexes were not purified further.
Duplex DNA-unwinding Assays—Purified helicase protein (typically 6 pmol) was incubated with the labeled duplex DNA (30 fmol) in 60 μl of Buffer G (20 mm Hepes, pH 7.4, 5 mm magnesium acetate, 2.5 mm ATP, 2 mm dithiothreitol, 0.1 mg/ml bovine serum albumin, 10% glycerol) for 10 min at 30 °C. Reactions were halted by the addition of 15 μl of gel loading buffer (5% SDS, 100 mm EDTA, 15% w/v Ficoll, 0.1% xylene cyanol, 0.05% bromphenol blue), and the products (25 μl) were immediately resolved on 15% polyacrylamide gels (29:1 acrylamide: bisacrylamide in (×1) TBE (89 mm Tris base, 89 mm boric acid, 10 mm EDTA)). For the positive control, labeled duplex DNA (30 fmol) in 60 μl of Buffer F was denatured by heating to 95 °C for 5 min and then flash cooling in liquid nitrogen. Gels were analyzed on a Storm 860 PhosphorImager using ImageQuaNT software (Amersham Biosciences).
Publication 2003
All colonoscopies were performed by two experienced board-certificated attending endoscopists and gastroenterologists who had performed more than 10,000 colonoscopies.
Colonoscope insertion in the cecum was accomplished using standard maneuvers. Small shaking, jiggling, and right-turn shortening maneuvers have been frequently used for insertion
9 (link)
. We started the colonoscopy with the patients in the left lateral position. Then, we placed the patients in the supine position after observation of the lower rectum. Extra gas and liquid were aspirated and removed as much as possible. We conducted colonoscopies using water-aided techniques with a 20-mL syringe placed directly through the colonoscope accessory channel for patients in the 260 group; we used the OFP-2 for patients in the 290 group
10 (link)
. For colonic insufflation, air was used for patients in the 260 group and patients in the 290 group with chronic respiratory failure; CO
2was administered through the UCR for patients in the 290 group without chronic respiratory failure.
Colonoscopies were performed under conscious sedation with midazolam (0.5 to 10 mg) and/or pethidine hydrochloride (17.5 to 70 mg). In the absence of contraindications, when the colonoscope reached the cecum, we administered 10 to 20 mg of scopolamine butylbromide.
Observation time for withdrawal of the colonoscope was standardized as at least 6 minutes
11 (link)
. PCC involved pan-colonic spraying with 0.05 % indigo carmine by a 20-mL syringe placed directly through the colonoscope accessory channel. We repeated administration of 5 mL indigo carmine with 10 mL air-spraying 10 to 20 times during the withdrawal procedure, and pools of excess dye were suctioned before examination. The colonoscope was sequentially withdrawn as the prescribed position changed
12 (link)
13 (link)
: the ascending colon/hepatic flexure was examined in the left lateral decubitus position; the transverse colon was examined in the supine position; the splenic flexure, descending colon, and sigmoid-descending colon junction were examined in the right lateral position; and the sigmoid colon and rectum were examined in the right lateral position. Physicians were permitted to change the position if it was medically necessary.
To endoscopically diagnose colorectal polyps, we used the updated Paris Endoscopic Classification of superficial neoplastic lesions in the digestive tract and the NICE (NBI International Colorectal Endoscopic) classification
14 (link)
15 (link)
. Lesions diagnosed as adenomas or sessile serrated polyps (SSPs) were removed by using hot or cold polypectomy with a snare or forceps or by endoscopic mucosal resection on the examination day. We did not resect the polyps with a diameter of 20 mm or more because they should be resected in the hospitalization facility.
Patients involved in this study underwent colonic preparation using 2 L of polyethylene glycol solution administered orally 5 hours before the procedure. Polyethylene glycol solution or magnesium citrate was added when the stool was not clear liquid. Quality of the bowel preparation was graded as A (all colon segments empty and clean or minor amount of fluid in the gut that was easily removed by suction), B (at least one colon segment with residual amounts of brown liquid or semi-solid stool that could be easily removed or displaced), C (at least one colon segment with only partially removable stool preventing complete visualization of mucosa), or D (at least one colon segment that could not be examined due to presence of remaining solid stool). The following colon segments were rated: rectum, sigmoid colon, descending colon, transverse colon, and ascending colon/cecum
16 (link)
. Patients with a grade of D during colonoscopy were excluded.
Publication 2019
[125I]-AngII was prepared with the iodogen method, and specific activity was determined from self-displacement and saturation experiments, as previously described4 . The density of cell surface receptors was evaluated with binding assays at 4 °C using [125I]-AngII as the tracer. HEK293 cells expressing either AT1R or AT1R-RlucII were seeded 1 day after transfection at a density of ∼120,000 cells per well in poly-L-ornithine-coated 24-well plates. The following day, cells were washed once with pre-warmed DMEM with 20 mM HEPES (DMEM-H) and then incubated in the absence or presence of 100 nM AngII in DMEM-H for 30 min at 37 °C. The plates were quickly washed three times with ice-cold acid (50 mM sodium citrate, pH 4.0) for 5 min each on ice to stop the stimulation and remove both the remaining surface bound and unbound AngII ligand. To remove and neutralize the residual acid, cells were further washed twice with ice-cold Tyrode's buffer. Cells were incubated with 0.5 ml of [125I]-AngII (∼250,000 c.p.m. at ∼2000, ci mmol−1) in binding buffer (0.2% BSA, 50 mM Tris, 100 mM NaCl2, 5 mM MgCl2, pH 7.4) at 4 °C overnight. Non-specific binding was determined in the presence of 1 μM AngII. The next day, cells were washed three times with ice-cold PBS with calcium and magnesium, and 0.5 ml of 0.5 M NaOH/0.05% SDS was added. Radioactivity from solubilized cells was counted using a PerkinElmer Wizard 1470 automatic γ-counter.
Full text: Click here
Publication 2016
Acids Biological Assay Buffers Calcium Cells Cold Temperature HEK293 Cells HEPES Iodo-Gen Ligands Magnesium Magnesium Chloride polyornithine Radioactivity Sodium Citrate Transfection Tromethamine

Most recents protocols related to «Magnesium citrate»

Example 1

NAME OF COMPONENTmg/sachet
Probiotic Material:
Lactobacillus helveticus150 billion CFU/g73.333
Rosell 52
Bifidobacterium longum 50 billion CFU/g20.000
R175
Lactobacillus plantarum150 billion CFU/g20.000
Rosell 1012
Carrier material:
Magnesium oxide41.446
Magnesium gluconate341.297
Potassium citrate138.290
Zinc gluconate111.111
Glutathione20.000
Lactoferrin11.364
Copper citrate2.834
Inulin500.000
Fructose1291.125
Additional (optional) excipients
Sucralose4.000
Acesulfame K12.000
Flavouring150.000
Aerosil 20040.000
Colouring: E1242.200
Colouring: E1021.000
Anhydrous citric acid220.000

The formulation described above is prepared as follows: Lactobacillus Plantarum, Lactobacillus helveticus, Bifidobacterium longum, are mixed with inulin and blended at 32 rpm for approximately 10 min. Thereafter, fructose, magnesium gluconate, zinc gluconate, citric acid, flavor, potassium citrate, magnesium oxide, silicon dioxide, glutathione, potassium acesulfame, lactoferrine, and sucralose are added to the mixture and blended at 32 rpm for another 10 min.

Full text: Click here
Patent 2024
acesulfame potassium Aerosil Bifidobacterium longum Citric Acid Citric Acid, Anhydrous Copper Excipients Flavor Enhancers Fructose gluconate Glutathione Inulin Lactobacillus Lactobacillus helveticus Lactobacillus plantarum Lactoferrin Magnesium magnesium gluconate Minerals Oxide, Magnesium Oxides Potassium Citrate Prebiotics Probiotics Salts Silicon Dioxide sucralose zinc gluconate
Participants within the intervention group were provided with 300 mg of oral magnesium supplement in the form of magnesium citrate capsules daily, and subjects in the control group received a placebo containing starch. Magnesium citrate powder was obtained from Behan Sar Pharmaceutical Company, and capsules containing magnesium and placebo were prepared by an expert at the Faculty of Pharmacy of Jundishapur University and provided to the study. The placebo capsules contained starch and were similar in appearance to magnesium supplements. The duration of intervention in patients was from the time of admission to the time of discharge from the hospital. In case of changes in the diet and medication protocol of the patients, the changes were reviewed by the research team, and in case of interference with the study objectives, the patient was excluded from the study.
Full text: Click here
Publication 2024
Not available on PMC !

Example 2

Lyophilization process: Measure amount of desired exosome solution. Add 1%-10% (e.g., 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%) by volume of a stabilizing agent selected from sucrose, mannitol or trehalose.

Carnosine functions as a biological pH buffer and antioxidant. Carnosine has protein stability benefits and prevents aggregation along with vasodilation benefits. Magnesium citrate is a magnesium salt used to regulate pH along with preservation.

Manufacturing Process for 1000 capsules each at 100 mg containing 5 mg exosome, 20 mg L-carnosine, and 75 mg magnesium citrate.

Materials: exosomes 5 grams, L-carnosine 20 grams, magnesium citrate 75 grams.

Steps for manufacturing: (1) calibrate scale; (2) accurately weigh out each of the materials using lab scoop; (3) sieve each material into one weighing dish; (4) add material to V-Blender; (5) turn on V-Blender and blend for 60 minutes; (6) empty material from V-Blender into clean weighing dish; (7) fill capsules with blended material.

Full text: Click here
Patent 2024
Antioxidants Biological Processes Biologic Preservation Buffers Capsule Carnosine Exosomes Freeze Drying Hyperostosis, Diffuse Idiopathic Skeletal Magnesium magnesium citrate Mannitol Sodium Chloride Stabilizing Agents Sucrose Trehalose Vasodilation
In October 2023, we visited three local pharmacies/drug stores in Freiburg, Germany and inquired about available citrate-based alkali supplements. In addition to that, we reviewed the available alkali supplements at several large online supplement retailers in Germany in early November 2023. Only citrate-based supplements were considered (defined as a citrate content > = 80% of the total alkali content). Supplements which included carbonates were only considered when the carbonate share was < 15% of the total content. To be considered eligible for this comparative review, supplements had to contain either potassium citrate, calcium citrate, magnesium citrate or any combination of these organic salts.
Supplement content (in g), the recommended daily dosage (RDD, in g) as well as the magnesium, potassium, sodium and calcium content of the respective supplements were reviewed. The PRAL was estimated per RDD with the following formula postulated by Remer and Manz [26 (link)]:
PRAL (mEq/RDD) = (0.49 * total protein content (g)) + (0.037 * phosphorus content (mg)) – (0.021 * potassium content (mg)) – (0.026 * magnesium content (mg)) – (0.013 * calcium content (mg)) -(0.041 * sodium content (mg)).
Sodium was added to the PRAL formula in order to increase the precision of our estimates, and because a few examined supplements contained sodium citrate (see results below), which also exerts alkalizing effects. For sodium, the conversion factor “0.041” was extracted from the work of Remer and Manz [26 (link)].
Moreover, we also calculated the so-called “total alkali load” (TAL) in mg, which is the sum of the following 4 alkalizing minerals: magnesium, potassium, sodium and calcium. The TAL (in mg) is not to be confused with the PRAL (in mEq), as the TAL reflects a (theoretical) indication of quantity.
In addition to that, we systematically captured the content of other minerals and vitamins included in each alkali supplement. Furthermore, we also reviewed whether the supplement was vegan (defined as not containing any animal-based components) or not, and whether the respective supplement was manufactured in Germany or not. In cases of doubt, we contacted the respective manufacturers by email and – if unsuccessful – by telephone. This information was collected to describe the examined dietary alkali supplements in as much detail as possible, allowing for a balanced and unbiased comparative analysis of the included products.
Full text: Click here
Publication 2024
Acetone, n-hexane of analytical grade, and petroleum ether for GC were obtained from Chempur, Poland. Salts used for extraction using the QuEChERS method included sodium chloride, magnesium sulfate, disodium citrate sesquihydrate, trisodium citrate (Chempur, Poland), together with sorbents used for clean-up – primary and secondary amines, PSA (Agilent, USA), and magnesium sulfate (Chempur, Poland). A certified mixture of standard solutions, EPA 525 PAHs Mix B, was obtained from Sigma-Aldrich, USA. Furthermore, methanol LC-MS (Honeywell, USA), 2,3,5-triphenyltetrazolium chloride – TTC (Sigma-Aldrich, USA) and 1,3,5-triphenyl tetrazolium formazan – TPF (Tokyo Chemical Industry, Japan) were used for the DHA analysis.
Full text: Click here
Publication 2024

Top products related to «Magnesium citrate»

Sourced in United States, Germany, United Kingdom, India, Italy, France, Spain, China, Canada, Sao Tome and Principe, Poland, Belgium, Australia, Switzerland, Macao, Denmark, Ireland, Brazil, Japan, Hungary, Sweden, Netherlands, Czechia, Portugal, Israel, Singapore, Norway, Cameroon, Malaysia, Greece, Austria, Chile, Indonesia
NaCl is a chemical compound commonly known as sodium chloride. It is a white, crystalline solid that is widely used in various industries, including pharmaceutical and laboratory settings. NaCl's core function is to serve as a basic, inorganic salt that can be used for a variety of applications in the lab environment.
Sourced in United States, Germany, United Kingdom, China, India, Spain, Italy, Switzerland, France, Brazil, Canada, Australia, Ireland, Sao Tome and Principe, Mexico, Macao, Portugal, Austria
Sodium citrate is a chemical compound commonly used in laboratory settings. It is a salt of citric acid and serves as a buffering agent, helping to maintain a specific pH level in solutions. Sodium citrate is a white, crystalline powder that is soluble in water.
Sourced in United States, Germany, United Kingdom, Macao, India, Australia, Singapore, France, Pakistan, Spain, Italy, China
Magnesium chloride is a chemical compound with the formula MgCl2. It is a white, crystalline solid that is highly soluble in water and other polar solvents. Magnesium chloride is a common laboratory reagent used in various applications.
Sourced in United States, Germany, United Kingdom, Italy, India, France, Spain, China, Belgium, Sao Tome and Principe, Canada, Denmark, Poland, Australia, Ireland, Israel, Singapore, Macao, Switzerland, Brazil, Mexico, Hungary, Netherlands, Egypt, Japan, Sweden, Indonesia, Czechia, Chile
Potassium chloride (KCl) is an inorganic compound that is commonly used as a laboratory reagent. It is a colorless, crystalline solid with a high melting point. KCl is a popular electrolyte and is used in various laboratory applications.
Sourced in Germany, United States, India, United Kingdom, Italy, China, Spain, France, Australia, Canada, Poland, Switzerland, Singapore, Belgium, Sao Tome and Principe, Ireland, Sweden, Brazil, Israel, Mexico, Macao, Chile, Japan, Hungary, Malaysia, Denmark, Portugal, Indonesia, Netherlands, Czechia, Finland, Austria, Romania, Pakistan, Cameroon, Egypt, Greece, Bulgaria, Norway, Colombia, New Zealand, Lithuania
Sodium hydroxide is a chemical compound with the formula NaOH. It is a white, odorless, crystalline solid that is highly soluble in water and is a strong base. It is commonly used in various laboratory applications as a reagent.
Sourced in Germany, United States, Italy, India, China, United Kingdom, France, Poland, Spain, Switzerland, Australia, Canada, Brazil, Sao Tome and Principe, Ireland, Belgium, Macao, Japan, Singapore, Mexico, Austria, Czechia, Bulgaria, Hungary, Egypt, Denmark, Chile, Malaysia, Israel, Croatia, Portugal, New Zealand, Romania, Norway, Sweden, Indonesia
Acetonitrile is a colorless, volatile, flammable liquid. It is a commonly used solvent in various analytical and chemical applications, including liquid chromatography, gas chromatography, and other laboratory procedures. Acetonitrile is known for its high polarity and ability to dissolve a wide range of organic compounds.
Sourced in Germany, United States, Italy, India, United Kingdom, China, France, Poland, Spain, Switzerland, Australia, Canada, Sao Tome and Principe, Brazil, Ireland, Japan, Belgium, Portugal, Singapore, Macao, Malaysia, Czechia, Mexico, Indonesia, Chile, Denmark, Sweden, Bulgaria, Netherlands, Finland, Hungary, Austria, Israel, Norway, Egypt, Argentina, Greece, Kenya, Thailand, Pakistan
Methanol is a clear, colorless, and flammable liquid that is widely used in various industrial and laboratory applications. It serves as a solvent, fuel, and chemical intermediate. Methanol has a simple chemical formula of CH3OH and a boiling point of 64.7°C. It is a versatile compound that is widely used in the production of other chemicals, as well as in the fuel industry.
Sourced in United States, Germany, United Kingdom, China, Hungary, Spain, Australia
Trisodium citrate is a common laboratory chemical used as a buffer and chelating agent. It maintains a stable pH and binds to metal ions in aqueous solutions.
Sourced in United States, Germany, United Kingdom, India, Italy, Spain, China, France, Macao, Canada, Sao Tome and Principe, Switzerland, Belgium, Japan, Norway, Brazil, Singapore, Australia
Calcium chloride is a salt compound that is commonly used in various laboratory applications. It is a white, crystalline solid that is highly soluble in water. The core function of calcium chloride is to serve as a desiccant, absorbing moisture from the surrounding environment. It is also used as a source of calcium ions in chemical reactions and analyses.
Sourced in Germany, United States, Italy, United Kingdom, France, Spain, China, Poland, India, Switzerland, Sao Tome and Principe, Belgium, Australia, Canada, Ireland, Macao, Hungary, Czechia, Netherlands, Portugal, Brazil, Singapore, Austria, Mexico, Chile, Sweden, Bulgaria, Denmark, Malaysia, Norway, New Zealand, Japan, Romania, Finland, Indonesia
Formic acid is a colorless, pungent-smelling liquid chemical compound. It is the simplest carboxylic acid, with the chemical formula HCOOH. Formic acid is widely used in various industrial and laboratory applications.

More about "Magnesium citrate"

Magnesium citrate is a widely used magnesium supplement that can help support healthy magnesium levels.
It is often utilized to address magnesium deficiencies and may provide additional health benefits.
PubCompare.ai's AI-powered platform can assist researchers in optimizing their protocols for studying magnesium citrate, locating the best published methods and identifying the most effective products.
This can streamline research efforts and enhance reproducibility, leading to improved results.
Magnesium citrate is a form of magnesium that is combined with citric acid, creating a water-soluble salt.
It is commonly used as a dietary supplement to increase magnesium intake, as well as a laxative to relieve constipation.
Magnesium is an essential mineral involved in over 300 bodily processes, including muscle and nerve function, energy production, and bone health.
In addition to its use as a magnesium supplement, magnesium citrate may also have other health benefits.
Some studies suggest that it may help to lower blood pressure, improve insulin sensitivity, and reduce the risk of certain types of cancer.
However, more research is needed to confirm these potential benefits.
When it comes to studying magnesium citrate, researchers can utilize PubCompare.ai's AI-driven platform to streamline their research efforts.
The platform allows users to locate the best published protocols, pre-prints, and patents, and identify the most effective products using AI-powered comparisons.
This can help to enhance the reproducibility of research findings and lead to improved results.
Researchers may also want to consider related compounds, such as sodium citrate, magnesium chloride, and calcium chloride, when designing their studies.
These compounds can be used in combination with magnesium citrate or as controls to better understand the effects of the supplement.
Overall, magnesium citrate is a widely used and potentially beneficial supplement that can be optimized for research purposes using PubCompare.ai's AI-powered platform.
By leveraging the insights and tools provided by the platform, researchers can enhance the efficiency and reproducibility of their studies, leading to more meaningful and impactful findings.